30-Second Takeaway
- ATAA mortality rises steeply with diameter, supporting a 5.5‑cm repair threshold while arguing for selective earlier surgery.
- Multivalve involvement in AS demands integrated imaging and heart‑team planning; evidence for add‑on percutaneous therapies remains limited.
- ESC/EACTS 2025 valve guidelines push earlier and more transcatheter intervention than current ACC/AHA documents.
- CABG RCTs rarely measure cognition and use insensitive tests, leaving postoperative neurocognitive risk largely unquantified.
- High‑risk support populations (transplant, t‑MCS, rheumatic MS) need refined risk tools, from bleeding predictors to LA strain and AI indices.
Week ending January 17, 2026
Timing complex cardiac interventions: new data on aortic aneurysm risk, valve guidelines, neurocognition, and advanced-support populations
VA cohort supports 5.5‑cm ATAA threshold but shows diameter‑linked mortality gradient
In 764 veterans with ascending thoracic aortic aneurysm ≥4.0 cm, overall dissection incidence under surveillance was extremely low (0.3%). All‑cause mortality rose stepwise with baseline diameter, with the highest death rates in aneurysms ≥5.5 cm. Each 0.5‑cm increase in diameter independently increased mortality risk (aSHR 1.36), even after adjusting for age and comorbidities. Aneurysms ≥5.5 cm had roughly sevenfold higher mortality incidence than smaller aneurysms, supporting the current 5.5‑cm prophylactic repair threshold. The data argue for maintaining the 5.5‑cm trigger while individualizing earlier surgery in selected high‑risk smaller aneurysms.
Multivalve disease in AS requires tailored combined surgical and transcatheter strategies
Many patients with severe aortic stenosis have concomitant multi‑valve lesions that significantly influence outcomes after SAVR or TAVR. The review emphasizes integrating hemodynamics and multimodality imaging to decide which additional valves to treat and by what modality. It notes growing adoption of staged or combined percutaneous interventions for secondary valve disease, despite sparse randomized data. The authors highlight the need for structured heart‑team evaluation and individualized sequencing rather than routine multivalve surgery or isolated TAVR. They call for trials to clarify when addressing concomitant MR or TR changes survival, symptoms, and reintervention rates.
ESC/EACTS 2025 vs ACC/AHA: earlier and more transcatheter valve intervention in Europe
This comparison review outlines key differences between 2025 ESC/EACTS and 2020 ACC/AHA valvular guidelines, plus a 2025 TR consensus. Both documents align on heart‑team use, prosthesis choice principles, and structured imaging, but diverge on timing and modality of intervention. European guidance incorporates newer trials to support earlier intervention in AS and AR and broader TEER/TMVR indications. ESC/EACTS explicitly integrates tricuspid repair and transcatheter options, and refines coronary assessment around TAVI more than ACC/AHA. Sex‑specific considerations are more developed in the European document, potentially affecting thresholds and modality selection in women.
CABG trials rarely and poorly measure postoperative cognitive outcomes
Among 2284 CABG randomized trials screened, only 71 (3.1%) reported any objective cognitive assessment. These 71 trials included 15,925 patients but used 145 different cognitive tasks, with substantial heterogeneity across studies. Common tests such as Trail Making A and B seldom detected perioperative cognitive change in control CABG arms. Average attrition approached 19%, reaching 62% in some studies, raising strong concerns about survivorship and selection bias. The review concludes current CABG RCTs are ill‑equipped to define neurocognitive risk, calling for standardized, sensitive, low‑attrition testing protocols.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.